Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 10

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 10
---

			Balance - September 30, 2023

			720,909

			$
			19.51

			Expired

			(111,192
			)

			7.26

			Balance - June 30, 2024

			609,717

			$
			21.74

The weighted average contractual life remaining on the outstanding warrants at June 30, 2025 is 31 months.

12

The following table summarizes information about the warrants outstanding at June 30, 2025:

			Number of Warrants (#)

			Exercise Prices 

			Expiry Dates

			173,614

			$
			10.50

			December 2025

			15,627

			$
			56.00

			February 2026

			27,399

			$
			31.94

			March 2027

			391,390

			$
			24.64

			September 2027

			326,560

			$
			3.45

			October 2029

			934,590

The fair value of warrants granted during the nine months ended June 30, 2024 was estimated using the Black-Scholes option valuation model using the following assumptions:

			Nine Months Ended June 30, 2025

			Class A Pref Share

			Risk free interest rate

			4.14
			%

			Expected life

			5 years

			Expected share price volatility

			91.24
			%

			Expected dividend yield

			0.00
			%

Share options 

The Company adopted an Equity Incentive Compensation Plan in 2019 (the 2019 Plan) administered by the independent members of the board of directors, which amended and restated prior plans. Options, restricted shares and restricted share units are eligible for grant under the 2019 Plan. The total number of shares available for issuance under the terms of the 2019 Plan is 2,367,737. The remaining number of shares available to grant at June 30, 2025 is 668,398.

The Company’s 2019 Plan allows options to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the option term is not to exceed